Clinical Trial Update: A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia [Phase 2]

View source ↗

Summary

The document notes the completion of a Phase 2 double-blind, placebo-controlled dose-exploration trial of CTI-1601 for Friedreich's Ataxia conducted by Larimar …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Friedreich Ataxia

Drugs mentioned

• CTI-1601

Snippet

Sponsor: Larimar Therapeutics, Inc. | Conditions: Friedreich Ataxia | Phase 2 | Status: COMPLETED